Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

£93 Million Package of Support Announced for UK’s Health Industries

Published: Wednesday, July 31, 2013
Last Updated: Wednesday, July 31, 2013
Bookmark and Share
Innovative business and academic projects will benefit from a new £93.2 million package of support.

The investment includes £25.9 million from Round 3 of the Biomedical Catalyst – a programme of public funding jointly managed by the Medical Research Council (MRC) and the Technology Strategy Board. Five universities and 29 companies will receive investment from the Catalyst.
 
One of the academic-led projects will see University of Newcastle use £1 million of MRC funding for a clinical trial to find out whether a drug developed to treat cancer can be repurposed to treat rheumatoid arthritis (RA) in patients who do not respond to existing treatments. The drug works by targeting a different type of cell from conventional therapies and could therefore succeed where conventional treatments have failed. The drug is being developed by Cyclacel Pharmaceuticals, a University of Dundee spin-out that has received two previous rounds of Biomedical Catalyst funding.
 
Another project led by The University of Manchester will use a £450,000 MRC grant to develop and test a smartphone app to deliver cognitive behavioural therapy (CBT) to people who have experienced a first episode of psychosis. If successful in patient trials, the Actissist app could help patients manage their condition more independently and prevent relapses of psychosis that often require unplanned admission to hospital. This would also lead to significant cost savings for the NHS.
 
As part of the recent Government’s Spending Review in June 2013, it was announced that there will be additional support for the Catalyst. Academic researchers and businesses can continue to apply for additional funding through the MRC and the Technology Strategy Board in Round 4 of the Biomedical Catalyst, which is now open.
 
In a further boost to the biomedical industry, a new £38 million National Biologics Manufacturing Centre (NBMC) will be based in Darlington. The centre, funded through investment announced as part of the life sciences strategy, will be a national base for the manufacturing of biological medicines such as antibodies and vaccines.
 
To complete the package of support, a further £29.3 million of investment in healthcare innovation has been announced through three Technology Strategy Board-led funding competitions. These will support businesses in areas such as stratified medicine and regenerative medicine.
 
Announcing the package of investment, Universities and Science Minister David Willetts said:
“By investing in new technologies now we are maintaining the UK’s position as a world leader for innovation. The biomedical industry is a fast moving, high growth sector and the Catalyst has proven to be extremely successful in supporting new business ideas. This investment further drives forward our life sciences strategy.
 
“The new National Biologics Manufacturing Centre will significantly increase the UK’s manufacturing capability in biologics, keeping us ahead in the global race and strengthening the UK’s position as the location of choice for life sciences companies.”
 
Professor Sir John Savill, Chief Executive of the MRC, said:

“Several of the MRC and Technology Strategy Board awards announced today build on previous MRC funding and this research is now reaching an exciting stage of clinical development. It’s fantastic to see this investment beginning to bear fruit. It clearly demonstrates that the Biomedical Catalyst is fulfilling its goal of providing seamless support from early research in universities through to commercialisation by small and medium-sized companies. We look forward to continuing our successful collaboration with the Technology Strategy Board into round 4 and beyond.”
 
Chief Executive of the Technology Strategy Board, Iain Gray said:

“The Biomedical Catalyst programme has already proved a significant success, providing the support companies need to develop their innovations and solve healthcare challenges.
 
“The projects funded through this latest round of the programme demonstrate both the innovative nature of the UK’s health R&D sector and the success of the programme in identifying projects with strong commercial potential.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

A Fundamental Protection Mechanism Against Formalin In Mammals is Revealed
Formaldehyde, or formalin, is well known to all of us as a common chemical used in many industrial processes and also as a preservative, remarkably we also produce formaldehyde in our bodies.
Wednesday, September 30, 2015
Redirecting the Rules of Attraction in Fruit Flies
MRC researchers have discovered a biological switch that determines which part of the fruit fly’s brain responds to pheromones, depending on whether the fruit fly is male or female.
Friday, December 20, 2013
A Gene Mutation for Excessive Alcohol Drinking Found
UK researchers have discovered a gene that regulates alcohol consumption and when faulty can cause excessive drinking.
Wednesday, November 27, 2013
New £23m Research Unit will use Advances in Genetics to Help Reduce Risk of Disease
Unit will exploit the latest advances in genetics to improve understanding of how changes to lifestyle or environment can reduce the risk of disease.
Monday, May 20, 2013
Gene Responsible for Increased Severity of Influenza in Chinese Populations
Researchers have found a genetic variant which explains why Chinese populations may be more vulnerable to the H1N1 form of flu, commonly known as swine flu.
Wednesday, January 30, 2013
World’s Largest Respiratory Genetics Study Launches on World COPD Day
Researchers funded by the Medical Research Council (MRC) are to conduct the largest ever study of the genetics relating to lung disease.
Thursday, November 15, 2012
A Phenomenal Legacy for London 2012
The Phenome Centre will use the cutting edge facilities developed for London 2012 to help develop better and more targeted treatment for patients.
Wednesday, August 01, 2012
MRC Cash Boost to Maximize Discovery of Mouse Models of Human Diseases
Medical Research Council to invest £61m over the next five years into mouse genetics research at MRC Harwell, Oxfordshire.
Monday, March 21, 2011
Polio Research Gives new Insight into Tackling Vaccine-Derived Poliovirus
Newly published research findings highlight the importance of completing polio eradication.
Friday, June 25, 2010
Scientists uncover new hereditary links to Alzheimer’s disease
Two genes which increase a person’s likelihood of developing the most common form of Alzheimer’s disease have been discovered in the largest-ever study of its kind into the illness.
Monday, October 05, 2009
Location of genetic varation is key to potential role in disease
Genetic variation is widely recognised as the key to survival and continued evolution of a species.
Friday, August 22, 2008
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Discovering the First Farmers
Genetic analyses reveal a collection of highly distinct groups in the Near East and Europe at the dawn of agriculture.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!